Dr. TJ Mundheim, DCThe question I get most often after someone decides to address their visceral fat is: semaglutide or tirzepatide? It is a good question. The answer is not one-size-fits-all, and anyone telling you otherwise is selling you something simple that is not actually simple.
Before I walk through the comparison, let me set the frame. Both of these medications work by reducing visceral fat — the metabolically active abdominal fat that drives systemic inflammation, disrupts insulin signaling, and produces the neuroinflammatory cascade that accelerates cognitive aging. Whether you lose 15% or 22% of your body weight, the downstream effect on brain health is significant. We are not chasing an aesthetic number. We are removing a source of neurological insult that compounds year over year if left unaddressed.
With that frame in place, here is what the data actually shows.
Mechanism of Action: Where They Differ
Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a gut hormone released after eating. It slows gastric emptying, promotes satiety, acts on appetite centers in the hypothalamus, and improves insulin sensitivity. Semaglutide mimics this hormone with a long half-life that allows for once-weekly dosing. It is a single-pathway drug — one receptor target, well-characterized over years of clinical use.
Tirzepatide is a dual GLP-1/GIP receptor agonist. GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone with its own metabolic effects — enhanced insulin secretion, improved fat metabolism, and potentially direct effects on adipose tissue remodeling. Engaging both pathways simultaneously appears to produce additive — and in some outcomes, synergistic — metabolic effects. This dual mechanism is why tirzepatide consistently outperforms semaglutide in head-to-head weight loss comparisons, and why it shows particular promise for metabolic syndrome and insulin resistance.
Efficacy: What the Trial Data Shows
The STEP trial program studied semaglutide 2.4 mg in adults with obesity. Average weight loss across the trials was 15–17% of body weight over 68 weeks. Participants also experienced clinically meaningful improvements in waist circumference, blood pressure, lipid panels, and glycemic control — all of which are relevant to brain health, not just scale weight.
The SURMOUNT trial program studied tirzepatide in adults with obesity. At the highest dose (15 mg), average weight loss reached 20–22.5% of body weight over 72 weeks. More than a third of participants in SURMOUNT-1 lost more than 25% of their starting body weight — results approaching what is typically seen with bariatric surgery, without the surgical risk. The metabolic improvements were correspondingly greater.
A direct head-to-head trial (SURPASS-CVOT versus SELECT for cardiovascular outcomes) is underway, but the weight loss data already tells us tirzepatide moves more metabolic mass in less time. For men with high visceral fat burden, that may be the deciding factor.
Head-to-Head Comparison
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GLP-1 + GIP dual receptor agonist |
| Average Weight Loss | 15–17% body weight (STEP trials) | 20–22.5% body weight (SURMOUNT trials) |
| Administration | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Dose Range | 0.25 mg to 2.4 mg | 2.5 mg to 15 mg |
| Titration Period | 16–20 weeks to maintenance dose | 20–28 weeks to maintenance dose |
| Cardiovascular Outcome Data | Proven CV risk reduction (SELECT trial) | CV outcome trial ongoing (SURMOUNT-CVOT) |
| Common Side Effects | Nausea, vomiting, diarrhea, constipation | Nausea, diarrhea, decreased appetite, vomiting |
Side Effects and Tolerability
The side effect profiles of both medications are predominantly gastrointestinal and similar in character — nausea, diarrhea, vomiting, constipation, reduced appetite. These are most pronounced during the titration phase and improve significantly as the body adjusts over weeks 4 through 12.
Gradual dose escalation is non-negotiable with both medications. Starting low and titrating slowly is not just a comfort measure — it is how you stay on the medication long enough to see the results that matter. The 4M protocol running in parallel during Month 1 includes gut support (Biome NS Ultra gut-repair formula), anti-inflammatory nutrition, and sleep optimization — all of which help the GI adaptation process.
Eating smaller, lower-fat meals and staying well-hydrated reduces nausea significantly. This is not incidental advice — it is a standard part of your Month 1 protocol.
Cost and Access
Brand-name semaglutide and tirzepatide carry list prices that exceed $1,000 per month without insurance. The My4MLife program uses compounded versions of both medications through licensed compounding pharmacies, which substantially reduces out-of-pocket cost. Your prescriber will walk through current pricing options during your consult — cost should not be the barrier that keeps you from addressing something this important to your long-term health.
Which One Is Right for Your Protocol?
Here is how I think about it clinically. If you have established cardiovascular disease or high cardiovascular risk and you want the most robustly documented outcome data, semaglutide's SELECT trial results are hard to argue with. If you have high visceral fat burden, significant insulin resistance, or metabolic syndrome, tirzepatide's dual mechanism and greater average weight reduction make it the more aggressive metabolic tool.
Neither of these decisions should be made based on a blog post comparison. Your comprehensive 4M consult includes a full health history review, current metabolic markers, and a clinical recommendation from your contracted licensed telemedicine provider. That is where the right answer for your body and your protocol gets determined.